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Acetylcholine prioritises direct synaptic inputs from
entorhinal cortex to CA1 by differential modulation
of feedforward inhibitory circuits
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Pradeep J. Nathan3, Alastair J. H. Brown2 & Jack R. Mellor 1✉
Acetylcholine release in the hippocampus plays a central role in the formation of new
memory representations. An influential but largely untested theory proposes that memory
formation requires acetylcholine to enhance responses in CA1 to new sensory information
from entorhinal cortex whilst depressing inputs from previously encoded representations in
CA3. Here, we show that excitatory inputs from entorhinal cortex and CA3 are depressed
equally by synaptic release of acetylcholine in CA1. However, feedforward inhibition from
entorhinal cortex exhibits greater depression than CA3 resulting in a selective enhancement
of excitatory-inhibitory balance and CA1 activation by entorhinal inputs. Entorhinal and CA3
pathways engage different feedforward interneuron subpopulations and cholinergic mod-
ulation of presynaptic function is mediated differentially by muscarinic M3 and M4 receptors,
respectively. Thus, our data support a role and mechanisms for acetylcholine to prioritise
novel information inputs to CA1 during memory formation.
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Cognitive processing in the brain must continuously adaptto changing environmental situations. However, the sta-bility of physical connectivity within neuronal networks, at
least over relatively short timescales (<min), means that the brain
requires systems that can enact rapid functional network recon-
figurations. Release of neuromodulator transmitters via long-
range projections fulfils the requirements for functional
reconfiguration1 and occurs in response to situations that
demand behavioural or cognitive adaptation2. But the mechan-
isms by which neuromodulators such as acetylcholine reconfigure
neuronal networks remain largely unknown.
The widespread release of acetylcholine within the brain is
historically associated with arousal and attention3–6. More
recently it has also been found to be associated with unexpected
rewards or punishments7,8 signalling the need to update existing
representations with new salient information. To achieve this
acetylcholine must reconfigure neural networks in two key ways:
(i) open a window for encoding new memories or updating
existing ones, and (ii) prioritise new sensory information for
incorporation into memory ensembles9,10. Acetylcholine facil-
itates the induction of synaptic plasticity thereby opening a
window for the creation of memory ensembles11–16 and it
increases the output gain from primary sensory cortices enhan-
cing signal-to-noise for new sensory information17–19. It is also
proposed to prioritise sensory inputs from the neocortex into
memory ensembles within the hippocampus10,11,20,21 but this
critical component of the mechanism by which acetylcholine
gates the updating of memory representations has yet to be tested
in detail.
The hippocampus is a hub for the encoding, updating and
retrieval of episodic memories, enabling events to be placed into a
context. Individual items of information from the neocortex are
thought to be sparsely encoded and separated by strong lateral
inhibition in the dentate gyrus before being assembled into larger
memory representations within the recurrent CA3 network10,22.
These memory representations are then transferred via the
Schaffer collateral (SC) pathway to CA1 which also receives new
sensory information directly from the entorhinal cortex layer III
pyramidal neurons via the temporoammonic (TA) pathway
enabling CA1 to compare and integrate the new
information23–26. It is therefore predicted that acetylcholine
enhances the relative weights of TA inputs to CA1 over SC inputs
during memory formation10.
Perhaps counter-intuitively, acetylcholine inhibits both TA and
SC glutamatergic excitatory transmission in CA1. In the SC
pathway, this occurs via presynaptic muscarinic M4 receptors but
the identity of the receptors mediating depression at the TA
pathway is unclear27–29. The anatomical segregation of TA and
SC inputs to distal and more proximal dendritic locations on CA1
pyramidal neurons, respectively25, together with muscarinic
receptor specificity provide potential mechanisms for differential
sensitivity to acetylcholine and therefore altering the relative
weights of synaptic input. However, the evidence for this is
equivocal with exogenously applied cholinergic agonists indicat-
ing that SC transmission is more sensitive to cholinergic mod-
ulation than TA transmission21 but the reverse reported for
endogenous synaptically released acetylcholine28.
An alternative mechanism by which acetylcholine might
rebalance the relative weights of SC and TA inputs is the mod-
ulation of the intrinsic and synaptic properties of hippocampal
GABAergic interneurons30–33 which have a profound impact on
CA1 pyramidal neuron input integration rules and subsequent
output30,34. Feedforward interneurons in the SC pathway are
primarily perisomatic targeting basket cells expressing parvalbu-
min (PV) or cholecystokinin (CCK)34–38 whose inhibition is
strongly regulated by acetylcholine31,33 whereas the mediators of
feedforward inhibition in the TA pathway are primarily CCK or
neuropeptide Y (NPY) expressing interneurons34,37,38 that are
also potentially regulated by acetylcholine32,39. Moreover, feed-
back inhibition via oriens lacunosum moleculare (OLM) inter-
neurons, which specifically target the same distal dendritic
regions as the TA pathway, are directly excited by
acetylcholine30,40. This indicates that cholinergic modulation of
inhibition within the hippocampal circuit regulates excitatory
input integration and CA1 output, but the integrated effect of
acetylcholine on the hippocampal network and its input-output
function has not been investigated.
In this study, we tested the hypothesis that acetylcholine release
in the hippocampus prioritises new sensory input to CA1 via the
TA pathway over internal representations via the SC pathway.
We find that endogenous synaptically released acetylcholine
depresses SC and TA excitatory inputs equally but that feedfor-
ward inhibition in the TA pathway is more sensitive to choli-
nergic modulation. This produces an increase in
excitatory–inhibitory ratio selectively for the TA pathway driven
by differential regulation of interneuron subpopulations and
distinct muscarinic receptor subtypes. We, therefore, provide a
mechanism by which acetylcholine dynamically prioritises sen-
sory information direct from the entorhinal cortex over internal
representations held in CA3.
Results
Endogenous acetylcholine release modulates synaptic inputs to
CA1. To enable selective activation of endogenous acetylcholine
release we expressed the light-activated cation channel
channelrhodopsin-2 (ChR2) in a cre-dependent manner using
mice that express cre recombinase under the control of the
promoter for Choline AcetylTransferase (ChAT-cre) crossed with
mice expressing cre-dependent ChR2 (ChAT-ChR2 mice; see
‘Methods’ section). Immunohistochemistry confirmed that ChR2
was expressed in cholinergic cells within the medial septum
(Fig. 1A, B) whose axon fibres densely innervated the dorsal
hippocampus (Fig. 1C) in agreement with the previously descri-
bed anatomy6. Whole-cell patch-clamp recordings from medial
septal neurons expressing ChR2 confirmed they fired action
potentials in response to 5 ms of 470 nm light up to a maximum
frequency of ~25 Hz (Fig. 1B). We also confirmed that light sti-
mulation in hippocampal slices resulted in acetylcholine release.
Recordings from interneurons located in Stratum Oriens revealed
fast synaptic responses to light stimulation mediated by nicotinic
receptors (Fig. 1D) consistent with activation of cholinergic axons
and endogenous release of acetylcholine30. In these recordings
and further recordings from CA1 pyramidal cells, we saw no
inhibitory post-synaptic currents that might be caused by light-
evoked co-release of GABA or excitatory glutamatergic currents
from either local or long-range ChAT-expressing neurons
(Fig. 1E)41,42.
To selectively activate the Schaffer collateral and temporoam-
monic pathways into CA1 stimulating electrodes were placed
within the two axon pathways in dorsal hippocampal slices. This
enabled independent stimulation of each pathway and the
engagement of both the direct excitatory inputs and disynaptic
feedforward inhibitory inputs without activating direct inhibitory
inputs, demonstrated by the blockade of inhibitory inputs by
NBQX (20 µM) (Supplementary Fig. S1A, B). We also pharma-
cologically confirmed the identity of the TA input by application
of the mGluR group II/III agonist DCG-IV (3 µM) that selectively
inhibits glutamate release from temporoammonic pathway
terminals43 (Supplementary Fig. S1C).
To test the effect of endogenous acetylcholine release on
synaptic inputs to CA1, hippocampal slices were stimulated with
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Fig. 1 Endogenous release of acetylcholine reduces excitatory and inhibitory synaptic inputs to CA1 pyramidal neurons. A Coronal section illustration of
medial septum (MS, yellow) and its projections to dorsal hippocampus including Schaffer collateral (green) and temporoammonic (purple) inputs to CA1
from CA3 and entorhinal cortex (EC), respectively. B Example recording of ChR2-YFP expressing cholinergic neuron in medial septum. Left,
immunofluorescence images showing cholinergic neuron (arrow) in medial septum filled with neurobiotin (purple) and expression of ChR2-YFP protein
(green). Higher magnification images below show ChR2-YFP on the membrane. Right, light-evoked stimulation of cholinergic neuron (blue dot, 10 ms)
reliably elicits action potentials at frequencies <25 Hz. Representative example of four independent recordings. C Immunofluorescence of CA1 area of the
hippocampus highlighting a CA1 pyramidal neuron filled with neurobiotin (light blue) and surrounding cholinergic axons (yellow). Nuclei stained with DAPI
(dark blue) and location of Schaffer collateral (SC) and temporoammonic (TA) axons illustrated in green and purple, respectively. Representative example
of 5 separate slice images. D Light stimulation of cholinergic fibres (blue dot) elicits fast synaptic responses in Stratum Oriens interneurons recorded at
−60 mV that are sensitive to atropine (25 µM) and mecamylamine (50 µM) but not picrotoxin (PTX, 50 µM), NBQX (20 µM) or D-APV (25 µM). E No
response to light stimulation of cholinergic fibres (blue dot) was seen in CA1 pyramidal neurons recorded at 0mV or −60 mV in contrast to electrical
stimulation of SC axons (black line). F SC (green) and TA (purple) evoked EPSCs in CA1 pyramidal neurons are reversibly depressed by 2 Hz light
stimulation (LED) of cholinergic fibres for 5 minutes (top). The depression of EPSCs is blocked by the application of cholinergic antagonists atropine
(25 µM) and mecamylamine (50 µM) (Bottom). G, H Acetylcholine release depressed SC and TA pathway-evoked EPSCs (G; SC pathway, n= 12 from 6
mice, p= 0.0002; TA pathway, n= 20 from 9 mice, p= 0.0002; SC – TA comparison, p= 0.46) and increased paired-pulse ratio (H, PPR; SC pathway,
p= 0.021; TA pathway, p= 0.008; SC – TA comparison, p= 0.52). Nicotinic and muscarinic receptor antagonists atropine (25 µM) and mecamylamine
(50 µM) blocked the effects of acetylcholine release on EPSCs (SC pathway, n= 6 from 3 mice, p= 0.73; TA pathway, n= 6 from 3 mice, p= 0.75) and
PPR (SC pathway, p= 0.86; TA pathway, p= 0.61). I Feedforward disynaptic IPSCs evoked by stimulation of SC and TA pathways are depressed by light
stimulation of cholinergic fibres (top). The depression of IPSCs is blocked by the application of cholinergic antagonists atropine and mecamylamine
(bottom). J, K Effects of acetylcholine release on SC and TA pathway-evoked IPSC response (J SC pathway, n= 16 from 10 mice, p= 0.001; TA pathway,
n= 16 from 11 mice, p= 0.009; SC – TA comparison, p= 0.28) and PPR (K SC pathway, p= 0.006; TA pathway, p= 0.75; SC – TA comparison, p= 0.011).
Cholinergic receptor antagonists blocked the effects of acetylcholine release on IPSCs (SC pathway, n= 5 from 4 mice, p= 0.17; TA pathway, n= 6 from 4
mice, p= 0.26) and PPR (SC pathway, p= 0.64; TA pathway, p= 0.95). Data are mean ± SEM; inter-group comparisons one-way ANOVA with post hoc
Bonferroni correction. Within-group comparisons two-tailed paired t-test ***p < 0.001 **p < 0.01 *p < 0.05. Source data are provided as a Source Data file.
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light at a frequency of 2 Hz for 5 min to evoke physiologically
maximal acetylcholine release44. In the presence of the GABAA
receptor antagonist picrotoxin, isolated SC and TA pathway
excitatory post-synaptic current (EPSC) amplitudes were
depressed by very similar amounts (Fig. 1F, G; SC pathway
69 ± 5%, n= 12 from 6 mice, p < 0.001; TA pathway 79 ± 4%,
n= 20 from 9 mice, p < 0.001) with a concomitant increase in the
paired-pulse ratio (PPR) (Fig. 1H; SC pathway, 125 ± 9%, p < 0.05;
TA pathway, 119 ± 5%, p < 0.01), indicating a presynaptic locus of
action. Application of nicotinic and muscarinic receptor antago-
nists atropine (25 µM) and mecamylamine (50 µM) blocked the
effects of endogenous acetylcholine release (Fig. 1F–H; SC
pathway 116 ± 8%, n= 6 from 3 mice, p > 0.05; TA pathway
106 ± 15%, n= 6 from 3 mice, p > 0.05). Therefore, contrary to
our initial hypothesis10,20,21,28, acetylcholine did not inhibit one
pathway more than the other but instead depressed both equally.
We next tested disynaptic feedforward inhibitory post-synaptic
currents (IPSCs) in response to stimulation of SC or TA pathways.
The amplitude of evoked IPSCs was also reduced by endogenous
acetylcholine release (Fig. 1I, J; SC pathway, 69 ± 5%, n= 16 from
10 mice, p < 0.01; TA pathway, 76 ± 4%, n= 16 from 11 mice,
p < 0.01) but surprisingly IPSC PPR was only increased in the SC
pathway (Fig. 1I, K; SC pathway, 132 ± 10%, p < 0.05; TA pathway,
101 ± 6%, p > 0.05). Similar to EPSCs, the reduction in IPSCs was
completely blocked by muscarinic and nicotinic receptor antago-
nists (Fig. 1I–K; SC pathway IPSC 122 ± 6% and PPR 106 ± 10%,
n= 5 from 4 mice, p > 0.05; TA pathway IPSC 98 ± 6% and PPR
99 ± 6%, n= 6 from 4 mice, p > 0.05). The observation that IPSCs
were depressed equally in each pathway but PPR was increased in
the SC pathway suggests that during repetitive stimulation
inhibitory drive will increase in the SC pathway relative to the
TA pathway. This predicts that although acetylcholine depresses
excitatory synaptic transmission in the TA and SC pathways
equally, its overall effect on excitatory–inhibitory ratio favours TA
inputs during repetitive stimulation when the effects of acetylcho-
line on feedforward inhibition are taken into account.
Cholinergic modulation of excitatory–inhibitory ratio for
inputs to CA1. To test whether excitatory–inhibitory balance was
differentially altered between SC and TA input pathways we
recorded monosynaptic EPSCs and disynaptic feedforward IPSCs
for SC and TA pathways in the same CA1 pyramidal neuron (see
‘Methods’ section; Fig. 2A). 5 consecutive stimuli at 10 Hz were
given alternately to SC then TA pathway to determine the evo-
lution of synaptic modulation by acetylcholine during a repetitive
train of stimuli. In these experiments, we again used light sti-
mulation of cholinergic fibres (2 Hz for 5 min). The depression of
EPSCs and IPSCs with the endogenous release of acetylcholine
occurred for all responses in both SC and TA pathways (Fig. 2B
and Supplementary Fig. S2D, E; SC pathway EPSC, 63 ± 5%,
n= 20 from 13 mice; TA pathway EPSC, 81 ± 7%, n= 19 from 12
mice; SC pathway IPSC, 70 ± 6%, n= 20 from 13 mice; TA
pathway IPSC, 75 ± 4%, n= 19 from 12 mice) but the degree of
depression was not consistent between pathways over the course
of repetitive stimulation. Cholinergic receptor activation
enhanced synaptic facilitation and increased PPR for excitatory
and feedforward inhibitory connections in the SC pathway, while
the TA pathway only displayed a marked increase in PPR in
excitatory but not feedforward inhibitory inputs (Fig. 2B and
Supplementary Fig. S2D, E; 5th stimuli PPR change for SC EPSC,
148 ± 10%, p < 0.01; SC IPSC, 198 ± 32%, p < 0.001; TA EPSC,
134 ± 10%, p < 0.001; TA IPSC, 116 ± 8%, p > 0.05), supporting
the initial results from Fig. 1. Indeed, the close similarity in PPR
increase for both excitatory and feedforward inhibitory trans-
mission in the SC pathway ensured that the excitatory–inhibitory
(E–I) ratio in the SC pathway did not change after cholinergic
receptor activation for any stimuli within the train (Fig. 2C; 5th
stimuli on SC E–I ratio, 0.57 ± 0.09 and 0.45 ± 0.07, for baseline
and light stimulation, respectively, p > 0.05). Conversely,
excitation-inhibition ratio in the TA pathway showed a marked
increase after CCh application that evolved over the course of the
train of stimuli (Fig. 2C; 5th stimuli on TA E–I ratio, 0.75 ± 0.16
and 0.88 ± 0.19, for baseline and light stimulation, respectively,
p < 0.01). This meant that over the course of the train the TA
input exerted relatively greater influence over the post-synaptic
neuron compared to the SC input when cholinergic receptors
were activated, as demonstrated by the comparison of excitation-
inhibition ratio between the SC and TA pathways (Fig. 2D; 5th
stimuli on TA/SC E–I ratio, 1.61 ± 0.32 and 2.45 ± 0.45, for
baseline and CCh, respectively, p < 0.01).
We also tested whether we could mimic the release of
endogenous acetylcholine with the application of the cholinergic
receptor agonist carbachol (CCh), a non-hydrolysable analogue of
acetylcholine that is not selective between cholinergic receptor
subtypes. This is important for mechanistic investigations where
optogenetic stimulation of cholinergic fibres are not compatible
with pharmacological manipulations or optogenetic stimulation
of interneurons. Application of increasing concentrations of CCh
revealed that 10 µM CCh was required to induce depression for
both EPSCs and IPSCs in both SC and TA pathways similar to
endogenous acetylcholine release (Supplementary Fig. S2F; SC
pathway EPSC, 35 ± 6%, n= 20 from 11 mice; TA pathway EPSC,
50 ± 5%, n= 20 from 11 mice; SC pathway IPSC, 29 ± 3%, n= 20
from 11 mice; TA pathway IPSC, 40 ± 4%, n= 20 from 11 mice),
but at lower concentrations of CCh SC excitatory synaptic
transmission showed higher sensitivity to CCh than the TA
pathway21 suggestive of different receptor affinities or signalling
pathways regulating presynaptic release (Supplementary Fig. S2A;
CCh 1 µM at SC pathway, 52 ± 6%, n= 9 from 4 mice; TA
pathway, 91 ± 18%, n= 9 from 4 mice). CCh and endogenous
acetylcholine also produced remarkably similar differentiation of
inhibitory short-term plasticity dynamics between SC and TA
pathways resulting in a robust increase in E–I ratio for the TA
pathway relative to the SC pathway (Fig. 2E–G and Supplemen-
tary Fig. S2B, C; 5th stimuli PPR change for SC EPSC, 197 ± 23%,
p < 0.01; SC IPSC, 188 ± 13%, p < 0.001; TA EPSC, 170 ± 13%,
p < 0.001; TA IPSC, 120 ± 13%, p > 0.05, n= 20 from 11 mice; 5th
stimuli on SC E–I ratio, 0.29 ± 0.05 and 0.41 ± 0.10, for baseline
and CCh, respectively, p > 0.05; 5th stimuli on TA E–I ratio,
0.34 ± 0.06 and 0.6 ± 0.10, for baseline and CCh, respectively,
p < 0.001; 5th stimuli on TA/SC E–I ratio, 1.28 ± 0.25 and
1.7 ± 0.25, for baseline and CCh, respectively, p < 0.01).
Analysis of the cumulative inhibitory drive across the 5 stimuli
revealed that CCh or endogenous acetylcholine reduced inhibi-
tion to a much greater extent in the SC pathway compared to the
TA pathway (Supplementary Fig. S2G, H) highlighting that
differential modulation of feedforward inhibition between SC and
TA pathways by cholinergic receptor activation produces an
increase in the relative strength of the TA input to CA1 pyramidal
neurons. Furthermore, the data suggest that SC and TA pathways
engage distinct local inhibitory interneuron populations with
different overall short-term dynamic responses to acetylcholine.
Cholinergic modulation of feedforward inhibitory synaptic
transmission. Feedforward interneurons in the SC pathway are pri-
marily perisomatic targeting basket cells expressing parvalbumin
(PV+) or cholecystokinin (CCK+) whereas the mediators of feedfor-
ward inhibition in the TA pathway are likely dendritically targeting
CCK+ or neuropeptide Y (NPY+) expressing interneurons34–38.
Analysis of our recordings revealed that feedforward SC IPSCs had
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faster decay kinetics than TA IPSCs (Fig. 3A–C; SC IPSC decay tau,
43.0 ± 2.7ms, n= 45 from 24 mice vs TA IPSC decay tau,
60.1 ± 3.4ms, n= 92 from 36 mice, p< 0.005). This confirms the sti-
mulation of distinct interneuron populations and signifies either dis-
tinct GABAergic subunits at those synapses or that the more distal
synaptic location of inhibitory inputs from TA feedforward inter-
neurons and therefore increased dendritic filtering means that these
IPSCs have slower kinetics34. GABAergic synapses from PV+ and
NPY+, but not CCK+, interneurons onto CA1 pyramidal cells are
depressed by µ-opioid receptors45–47. SC IPSCs were more sensitive to
µ-opioid receptor agonist DAMGO (1 µM) than TA IPSCs (Fig. 3D, E;
IPSC 1st response peak after DAMGO, 51 ± 4% and 69 ± 5%, for SC
and TA, respectively, n= 11 from 4 mice, p< 0.05) indicating that in
our experiments PV+ interneurons form a major component of
feedforward inhibition in the SC pathway whereas CCK+ interneurons
form the major component of feedforward inhibition in the TA
pathway. There are also minor components from other interneuron
subtypes, most likely CCK+ basket cells in the SC pathway and PV+
or NPY+ interneurons in the TA pathway34–38 that suggests some
overlap in interneuron populations between the SC and TA pathways.
The engagement of different interneuron subtypes in feedfor-
ward inhibition in the SC and TA pathways might explain the
differential modulation of feedforward inhibition by acetylcho-
line. Therefore, we investigated whether the output from these
interneurons onto CA1 pyramidal cells is modulated by
acetylcholine and, if so, whether modulation evolves differentially
for the 2 inputs during a burst of responses. To test this we used
mice expressing ChR2 in PV+ or CCK+ interneurons (see
‘Methods’ section) and gave a train of 5 light stimuli at 10 Hz to
the slices whilst recording IPSCs from pyramidal neurons at
0 mV in the presence of NBQX and D-APV to avoid recording
glutamatergic, disynaptic inhibitory inputs or ChR2 currents
(Supplementary Fig. S3). We and others have demonstrated that
neurons expressing ChR2 fire action potentials reliably at 10 Hz
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Fig. 2 Acetylcholine release enhances excitatory–inhibitory balance for temporoammonic synaptic inputs relative to Schaffer collateral inputs.
A Middle, schematic representation of the experimental approach incorporating simultaneous recording of excitatory (Vh=−60 mV) and feedforward
inhibitory (Vh= 0mV) synaptic inputs from Schaffer collateral (SC) and temporoammonic (TA) input pathways to CA1 pyramidal neuron (bottom).
Example traces for EPSCs and IPSCs in response to trains of 5 stimuli at 10 Hz to SC (green, left) and TA (purple, right) pathways before and after light
stimulation (LED) of cholinergic fibres at 2 Hz for 5 min. B Change in paired-pulse ratio (PPR) after light stimulation of cholinergic fibres for excitatory and
inhibitory responses to SC (left) and TA (right) pathway stimulation (5th stimuli PPR change for SC EPSC, n= 20 from 13 mice, p= 0.010; SC IPSC,
p= 0.007; TA EPSC, p= 0.003; TA IPSC, p= 0.073). PPR is measured compared to the first response for each response in the train. C Comparison of
synaptic Excitatory–Inhibitory (E–I) ratio before and after light stimulation measured by charge transfer at Vh=−60 mV and 0mV for SC (left) and TA
(right) input pathways (5th stimuli on SC E–I ratio, p= 0.059; TA E–I ratio, p= 0.007). D Comparison of synaptic E–I ratio between TA and SC input
pathways before and after light stimulation. Acetylcholine release enhanced the overall relative synaptic charge transfer from the TA pathway (5th stimuli
on TA-SC E–I ratio, p= 0.016). E–G similar quantification to B–D for experiments using bath applied exogenous carbachol (CCh, 10 µM) (E 5th stimuli PPR
change for SC EPSC, n= 20 from 11 mice, p= 0.002; SC IPSC, p= 0.00002; TA EPSC, p= 0.0003; TA IPSC, p= 0.220. F 5th stimuli on SC E–I ratio,
p= 0.285; TA E–I ratio, p= 0.0002. G 5th stimuli on TA-SC E–I ratio, p= 0.002). Data are mean ± SEM; comparisons are two-tailed paired t-test
***p < 0.001, **p < 0.01, *p < 0.05. Source data are provided as a Source Data file.
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with this stimulation protocol (Fig. 1)38,48,49. To test the
sensitivity of PV+ and CCK+ synapses to cholinergic modulation,
CCh was bath applied to the slice whilst selectively evoking either
PV+ or CCK+ derived IPSCs (Fig. 3F). PV+ evoked IPSCs
displayed faster decay kinetics to CCK+ evoked IPSCs confirming
the stimulation of separate interneuron populations (Fig. 3G;
PV+ decay kinetics, 14.9 ± 1.8 ms, n= 7 vs CCK+ decay kinetics,
21.9 ± 3.4 ms, n= 5, p < 0.05). The decay kinetics correlate with
the inferred contribution of PV+ and CCK+ interneurons to SC
and TA feedforward pathways and again suggests their periso-
matic and dendritic synaptic locations, respectively. Decay
kinetics of optogenetically evoked IPSCs were faster than
disynaptically evoked feedforward IPSCs as predicted for inputs
with greater synchrony. CCh depressed IPSCs from both PV+
and CCK+ synapses indicating a direct cholinergic modulation of
these interneurons (Fig. 3F, H; PV+ responses, 34.3 ± 6.0%, n= 7,
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Fig. 3 Cholinergic modulation of inhibitory inputs from distinct feedforward interneuron populations. A Schematic representation of different
feedforward interneuron populations engaged by Schaffer collateral (SC) and temporoammonic (TA) pathways within CA1. B, C Disynaptic feedforward
IPSCs (B) and distribution of decay kinetics (C) for Schaffer collateral (SC, green) and temporoammonic (TA, purple) input pathways demonstrating
distinct populations of feedforward interneurons. Quantification of the IPSC tau decay (insert C) (SC, n= 45 from 24 mice; TA, n= 92 from 36 mice;
p= 0.0002). D µ-opioid receptor agonist DAMGO (1 µM) depression of disynaptic feedforward IPSCs from SC and TA pathways (SC vs TA pathways,
n= 11 from 4 mice, p= 0.015). E IPSC decay kinetics and sensitivity to DAMGO correlate and distinguish SC from TA evoked IPSCs. F Optogenetic
activation of either PV (top) or CCK (bottom) interneurons at 10 Hz evoked a train of IPSCs in CA1 pyramidal neurons. IPSCs from both interneurons are
depressed by CCh (10 µM). G, H IPSCs from PV interneurons display faster decay kinetics than IPSCs from CCK interneurons (G PV, n= 7; CCK, n= 5;
p= 0.02) but CCh depressed the IPSC amplitudes of the first responses in the train by a similar amount (H PV, n= 7, p < 0.0001; CCK, n= 5, p < 0.0001).
I, J IPSCs from both PV and CCK interneurons demonstrated frequency-dependent depression. Frequency-dependent depression was reduced after CCh
application for PV (top; n= 7, p= 0.010) but not CCK (bottom; n= 5; p= 0.172) evoked IPSCs. Data are mean ± SEM; Comparisons are two-tailed paired
t-test ***p < 0.001, **p < 0.01, *p < 0.05. Source data are provided as a Source Data file.
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p < 0.005; CCK+ responses, 37.8 ± 4.8%, n= 5, p < 0.005). Both
synapses exhibited frequency-dependent depression but CCh
selectively increased PPR of PV+ but not CCK+ synapses (Fig. 3I,
J; PV+ IPSC PPR, 136 ± 11%, n= 7, p < 0.05; CCK+ IPSC PPR,
104 ± 4%, n= 5, p > 0.05). The lack of effect of cholinergic
receptor activation on PPR at CCK+ synapses mirrors the lack of
effect on PPR for feedforward inhibition in the TA pathway
indicating that CCK+ interneurons are the major component of
feedforward inhibition in the TA pathway whereas PV+
interneurons and synapses that increase PPR form feedforward
inhibition in the SC pathway. The differential effect of acetylcho-
line at PV+ and CCK+ synapses provides a mechanism for the
enhancement of TA pathway excitatory–inhibitory ratio in
comparison to the SC pathway.
Presynaptic modulation of the temporoammonic pathway by
muscarinic M3 receptors. The synaptic depression of Schaffer
collateral inputs to CA1 by acetylcholine is characterised geneti-
cally and pharmacologically to be mediated by muscarinic M4
receptors27,29. This was confirmed by application of the dual
muscarinic M4 and M1 receptor agonist Compound 1 (1 µM;
Supplementary Fig. S4)50, which selectively depressed SC but not
TA pathway excitatory inputs (Fig. 4A–D; SC EPSC response,
63 ± 5%, n= 17, from 8 mice, p < 0.001; TA EPSC response,
94 ± 5%, n= 17, from 8 mice, p > 0.05). However, the identity of
cholinergic receptors mediating the depression of TA inputs is
unclear. Therefore, we aimed to determine which cholinergic
receptors modulate the TA pathway feedforward excitatory and
inhibitory synaptic transmission onto CA1 pyramidal neurons.
TA pathway excitatory synaptic transmission was isolated by
recording in the presence of PTX and holding the membrane
voltage at −65 mV (see ‘Methods’ section; Fig. 4E). Similar to
previous results (Figs. 1 and 2 and Supplementary Fig. S2), TA
EPSCs were depressed by application of 10 µM CCh and PPR was
increased (Fig. 4F; EPSC response, 43 ± 5%, n= 13 from 7 mice,
p < 0.01; PPR, 129 ± 8%, p < 0.05). These data suggest a pre-
synaptic locus of action of cholinergic receptors. We next phar-
macologically dissected which cholinergic receptor subtypes were
involved. Application of the non-selective nicotinic receptor
antagonist mecamylamine (25 µM) had no effect on CCh
depression of EPSCs (Fig. 4G; 40.6 ± 9.5%, n= 6 from 3 mice,
p < 0.01) and PPR (Fig. 4H; 124 ± 8%, n= 6 from 3 mice,
p < 0.05), while the non-selective muscarinic receptor antagonist
atropine (10 µM) blocked the decrease of EPSCs (Fig. 4G;
91 ± 4%, n= 6 from 3 mice, p > 0.05) and prevented the increase
in PPR (Fig. 4H; 105 ± 4%, n= 6 from 3 mice, p > 0.05), sug-
gesting a direct involvement of muscarinic receptors. Muscarinic
M1 receptor agonist GSK-5 (500 nM)16 did not replicate CCh
depression of EPSCs and increase in PPR (Fig. 4G, H; EPSCs, 91
± 4%, PPR 101 ± 5%, n= 7 from 4 mice, p > 0.05) nor did the
selective M1 receptor antagonist, nitrocaramiphen (1 µM) prevent
CCh-induced depression and increase in PPR (Fig. 4F–H; EPSC
51 ± 4%, n= 6 from 4 mice, p < 0.01; PPR 124 ± 6%, n= 6 from 4
mice, p < 0.05). The high density of muscarinic M3 receptors
localised to Stratum Lacunosum Moleculare where TA inputs
synapse in CA151 suggests a role for M3 receptors modulating the
TA pathway. Supporting a role for M3 receptors, the selective M3
receptor antagonist DAU5884 (1 µM)52 prevented the EPSC
depression and increase in PPR caused by CCh (Fig. 4G, H; EPSC
105 ± 11%, n= 6 from 4 mice, p > 0.05; PPR 101 ± 6%, n= 6 from
4 mice, p > 0.05) or endogenous acetylcholine (Fig. 4G, H;
DAU5884 amplitude response 101 ± 3%, n= 7 from 3 mice
p > 0.05; PPR 0.97 ± 4%, p > 0.05) suggesting that TA pathway
synaptic transmission onto CA1 pyramidal neurons is modulated
by muscarinic M3 receptors with a presynaptic locus of action.
To confirm the involvement of muscarinic M3 receptors, we
tested the effects of CCh in M3 receptor knockout mice (CHRM3
KO)53. Although TA evoked EPSCs recorded from CHRM3 KO
slices were reduced by CCh with an associated increase in PPR
(Fig. 4I–K; EPSC, 68 ± 4%, n= 20 from 11 mice, p < 0.001; PPR,
115 ± 5%, p < 0.05), this CCh-induced depression was less than
that recorded in CHRM3 WT slices (Fig. 4J; WT EPSC vs M3 KO
EPSC, p < 0.05). This confirms the pharmacological data for M3
receptor involvement in the TA pathway but also suggests some
compensation for M3 receptor deletion within M3 KO mice. The
most likely subunit to compensate for M3 deletion are M1
receptors that are also coupled to Gq signalling pathways.
Therefore, to further explore possible compensatory mechanisms,
we tested the selective muscarinic M1 receptor agonist GSK-5 in
the M3 KO mice (Supplementary Fig. S5). M1 receptor activation
depolarises and increases spike rates in pyramidal neurons12
thereby increasing spontaneous EPSCs. Application of GSK-5
increased spontaneous EPSC frequency in slices from both WT
and M3 KO mice (Supplementary Fig. S5A) but caused a selective
decrease in TA EPSC and the corresponding increase in PPR in
the M3 KO but not the WT (Supplementary Fig. S5B, C).
Furthermore, the M1 receptor antagonist nitrocaramiphen
blocked the actions of carbachol in the M3 KO mice
(Supplementary Fig. S5B, C). This indicates that M1 receptors
partially compensate for deleted M3 receptors to modulate
presynaptic TA terminals in M3 KO mice.
Feedforward synaptic inhibitory transmission in the TA
pathway was isolated by holding the membrane voltage at 0 mV
(see ‘Methods’ section; Fig. 4L, M). As previously described
(Figs. 1, 2 and Supplementary Fig. S2), CCh depressed IPSCs
without an effect on PPR (Fig. 4L–N; IPSC, 48 ± 6%, n= 9 from 4
mice, p < 0.01; PPR, 108 ± 3%, n= 9 from 4 mice, p > 0.05). The
pharmacological data again supported a role for M3 receptors.
Nicotinic receptor antagonist mecamylamine (25 µM) did not
prevent CCh-induced depression (Fig. 4N; 31 ± 6%, n= 5 from 3
mice, p < 0.01) but the muscarinic receptor antagonist atropine
(10 µM) did (Fig. 4N; 87 ± 5%, n= 6 from 3 mice, p > 0.05),
demonstrating that, as for excitatory synaptic transmission,
inhibitory inputs to CA1 pyramidal neurons are depressed by
muscarinic receptor activation. Muscarinic M1 receptors did not
alter TA IPSC as the agonist GSK-5 was unable to modulate
inhibitory synaptic transmission (Fig. 4N; GSK-5 500 nM;
83 ± 6%; n= 4 from 2 mice, p > 0.05) and the M1 receptor
antagonist nitrocaramiphen was unable to block the CCh effect
(Fig. 4N; nitrocaramiphen 1 µM, 49 ± 2%, n= 4 from 2 mice,
p < 0.01). Similar to excitatory transmission, muscarinic M3
receptor antagonist (DAU5884 1 µM) blocked TA pathway IPSC
modulation by CCh or endogenous release of acetylcholine
(Fig. 4N; CCh 84 ± 4%, n= 8 from 4 mice, p > 0.05 and LED
activation 93 ± 5%, n= 5 from 3 mice, p > 0.05). These results
indicate that M3 muscarinic receptors modulate presynaptic TA
terminals where they depress the release of glutamate onto CA1
pyramidal neurons and feedforward inhibition within the TA
pathway.
M3 receptors are expressed in entorhinal cortex pyramidal cells
that project in the TA pathway and immunohistochemistry
localises them preferentially to the stratum lacunosum moleculare
in CA1 where TA fibres terminate without distinguishing
between pre- or post-synaptic locations51. This evidence coupled
with our results suggests that M3 receptors are presynaptically
located at TA synapses, but it is unusual for Gq-coupled receptors
to regulate presynaptic function. Alternative mechanisms include
activation of post-synaptic M3 receptors causing excitation of
pyramidal cells or interneurons. These could lead to reduced TA
glutamate release by a retrograde messenger (such as an
endocannabinoid) or GABA spillover activating presynaptic
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GABAB receptors. To explore the location of M3 receptors we
performed three additional sets of experiments to test whether M3
receptors located on pyramidal cells or interneurons in CA131,32
regulate presynaptic neurotransmitter release. The first experi-
ment blocked post-synaptic M3 receptor function by the inclusion
of GDP-β-S in the patch pipette. This prevented the
depolarisation and increase in input resistance mediated by Gq-
coupled muscarinic receptors in response to the application of
10 µM CCh (Fig. 5C; membrane potential change, control
4.1 ± 0.9 mV, n= 21 from 13 mice, p < 0.001 and GDP-β-S
0.4 ± 1.4 mV, n= 7 from 3 mice, p > 0.05; input resistance change,
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S 0.9 ± 5.7 MΩ, n= 7 from 3 mice, p > 0.05) but had no effect on
the depression of excitatory TA pathway transmission when left
to diffuse into the dendrites for >15 min (Fig. 5D, G, H; control
EPSC 43 ± 5% and PPR 129 ± 8%, n= 13 from 8 mice; GDP-β-S
EPSC 51 ± 5% and PPR 114 ± 8%, n= 10 from 5 mice, p > 0.05).
The second experiment blocked GABAB receptors with
CGP55845 (5 µM) to prevent activation of presynaptic GABAB
receptors on TA pathway terminals. CGP55845 had no effect on
CCh-induced depression of excitatory TA pathway transmission
(Fig. 5E, G, H; CGP EPSC 52 ± 6% and PPR 118 ± 5%, n= 9 from
4 mice, p > 0.05 compared to CCh alone). The third experiment
blocked CB1 receptors with AM251 (1 µM). In the presence of
AM251 CCh still induced a substantial depression of excitatory
TA pathway transmission and caused an increase in PPR but the
depression was slightly less than CCh alone (Fig. 5F–H; AM251
EPSC 65 ± 4% and PPR 126 ± 9%, n= 12 from 4 mice, p < 0.01
for EPSC AM251 vs control). This suggests a minor component
of the TA pathway depression may be mediated by CB1 receptors.
However, taken together these experiments do not support a
major role for M3 receptors expressed on CA1 pyramidal cells or
interneurons in regulating presynaptic TA pathway function and
therefore support the conclusion that M3 receptors are pre-
synaptically located on TA pathway terminals.
Pathway specific cholinergic disinhibition of CA1 output. The
modulation of hippocampal synaptic transmission and in parti-
cular the differential regulation of excitatory–inhibitory balance
of SC and TA synaptic pathways predicts that acetylcholine
prioritises CA1 response to inputs from entorhinal cortex via the
TA pathway. To test this prediction, we monitored spike gen-
eration in CA1 pyramidal neurons in response to SC and TA
pathway stimulation using trains of 10 stimuli at 10 Hz given to
SC or TA pathways. The stimulus intensities were set so that
post-synaptic potentials (PSPs) were suprathreshold for action
potential initiation on some but not all stimuli (Pspike; see
‘Methods’ section). Light stimulation of cholinergic fibres (2 Hz
for 5 min) decreased the probability of spiking in response to SC
pathway stimulation (Fig. 6A–C; SC Pspike baseline 0.61 ± 0.04 vs
light stimulation 0.44 ± 0.06, normalised SC decrease 0.77 ± 0.1,
n= 13 from 8 mice, p < 0.05), whereas the probability of spiking
in response to TA pathway stimulation increased (Fig. 6A–C; TA
Pspike baseline 0.43 ± 0.05 vs light stimulation 0.62 ± 0.05, nor-
malised TA increase 1.71 ± 0.29, n= 14 from 7 mice, p < 0.005).
This opposite modulation of SC and TA pathways was striking in
a subset of recordings made from both pathways in the same
neuron (Pspike SC vs TA, n= 11, p < 0.05). These changes were
matched by an increase to the time to first spike in the SC
pathway and a decrease for the TA pathway (Fig. 6D; SC nor-
malised time to first spike 1.77 ± 0.28, p < 0.05 and TA
0.72 ± 0.05, p < 0.001). Analysis of the spike probability changes
for each experiment showed that the amount of spike probability
change was correlated with initial spike probability, but the
direction of change was not (Supplementary Fig. S7). This indi-
cates that although TA inputs target more distal dendrites and
therefore have a generally lower initial efficacy for spike genera-
tion this does not dictate the differential effects of acetylcholine
on the SC and TA pathways. Importantly, the effects of light
stimulation of cholinergic fibres on CA1 spike probability and
latency were completely blocked by the inclusion of muscarinic
and nicotinic antagonists (Fig. 6A, C, D; SC normalised Pspike
1.04 ± 0.1, n= 9 from 4 mice, p > 0.05 and TA 0.82 ± 0.16, n= 6
from 4 mice, p > 0.05; SC normalised time to first spike
0.86 ± 0.06, p > 0.05 and TA 1.33 ± 0.17, p > 0.05). Therefore,
endogenous acetylcholine release downregulates CA1 pyramidal
neuron responses to the SC pathway and upregulates responses to
the TA pathway.
Similar results were obtained using an exogenous application of
10 µM CCh, the major difference being that CCh depolarised
CA1 pyramidal neurons (average depolarisation 5.3 ± 0.7 mV).
To dissociate the effects of CCh on membrane potential and
synaptic inputs, current was initially injected to maintain
membrane potential at baseline (i ≠ 0) and assessed changes in
spike probability. Subsequently, the injected current was removed
(i= 0) to examine how cholinergic depolarisation affected spike
probability. With membrane potential maintained at baseline
levels, CCh dramatically reduced the probability of spikes
generated by SC pathway stimulation (Supplementary
Fig. S6A1–C1; Pspike baseline 0.59 ± 0.07 vs CCh i ≠ 0
0.14 ± 0.05, n= 12 from 5 mice, p < 0.001) and required more
stimuli within a train and therefore a longer delay to generate the
Fig. 4 Muscarinic M3 receptors modulate temporoammonic pathway EPSCs and disynaptic IPSCs in CA1 pyramidal neurons. A Schematic illustrating
recording of pharmacologically isolated EPSCs from temporoammonic (TA) and Schaffer collateral (SC) pathways. B–D The dual M1 and M4 and
muscarinic receptor agonist Compound 1 (1 µM) depressed evoked EPSCs (C) and increased paired-pulse ratio (PPR) (D) for SC (green) but not TA
(purple) pathway (SC EPSC, n= 17 from 8 mice, p < 0.001; TA EPSC, n= 17, from 8 mice, p= 0.29; SC vs TA EPSC comparison, p < 0.001; SC PPR,
p= 0.012; TA PPR, p= 0.265; SC vs TA PPR comparison, p= 0.005). E Schematic illustrating recording of pharmacologically isolated EPSCs from
temporoammonic (TA) pathway. F CCh (10 µM) reliably reduced evoked EPSC amplitudes. G, H Pharmacology of cholinergic depression of EPSCs. EPSC
depression induced by CCh or light stimulation of cholinergic fibres (G) is prevented by the application of muscarinic receptor antagonist atropine (Atrp,
10 µM) or M3 receptor antagonist DAU5884 (DAU, 1 µM) but not M1 receptor antagonist Nitrocaramiphen (NCP, 1 µM) or nicotinic receptor antagonist
mecamylamine (MEC, 25 µM) and is not replicated by M1 receptor agonist GSK-5 (500 nM). PPR changes reflect conditions of cholinergic-induced EPSC
depression (H) (CCh, n= 6 from 3 mice, EPSC p= 0.001, PPR p= 0.021; CCh+MEC, n= 6 from 3 mice, EPSC p= 0.001, PPR p= 0.037; CCh+Atrp,
n= 6 from 3 mice, EPSC p= 0.37, PPR p= 0.29; GSK-5, n= 7 from 4 mice, EPSC p= 0.32, PPR p= 0.52; CCh+NCP, n= 6 from 4 mice, EPSC p= 0.001,
PPR p= 0.020; CCh+DAU, n= 6 from 4 mice, EPSC p= 0.54, PPR p= 0.85; LED, n= 7 from 3 mice, EPSC p < 0.0001, PPR p= 0.007; LED+DAU, n= 6
from 3 mice, EPSC p= 0.80, PPR p= 0.41). I–K Comparison of the effects of CCh on TA pathway-evoked EPSCs in wild type (WT) and M3 receptor
knockout mice (M3 KO). EPSC depression (J) and PPR increase (K) by CCh were reduced in slices from M3 KOs in comparison to WT (WT EPSC, n= 9
from mice, p < 0.0001; KO EPSC, n= 20 from 11 mice, p= 0.0001; WT vs KO EPSC, p= 0.03; WT PPR, p= 0.022; KO PPR, p= 0.020). L Schematic
illustrating recording of disynaptic feedforward IPSCs from pyramidal neurons at 0mV in TA pathway. M CCh (10 µM) reliably reduced evoked IPSC
amplitudes. N Pharmacology of cholinergic depression of IPSCs. IPSC depression induced by CCh or light stimulation of cholinergic fibres is prevented by
the application of muscarinic receptor antagonist atropine or M3 receptor antagonist DAU5884 but not M1 receptor antagonist Nitrocaramiphen or
nicotinic receptor antagonist mecamylamine and is not replicated by M1 receptor agonist GSK-5 (CCh, n= 9 from 4 mice, EPSC p= 0.004; CCh+MEC,
n= 5 from three mice, EPSC p= 0.001; CCh+Atrp, n= 6 from 3 mice, EPSC p= 0.64; GSK-5, n= 4 from 2 mice, EPSC p= 0.34; CCh+NCP, n= 4 from
2 mice, EPSC p= 0.003; CCh+DAU, n= 8 from 4 mice, EPSC p= 0.17.; LED, n= 5 from 3 mice, EPSC p= 0.003; LED+DAU, n= 5 from 3 mice, EPSC
p= 0.18). Data are mean ± SEM; inter-group comparisons one-way ANOVA with post hoc Bonferroni correction. Within-group comparisons two-tailed
unpaired t-test ***p < 0.001, **p < 0.01, *p < 0.05. Source data are provided as a Source Data file.
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first spike (Supplementary Fig. S6A1–C1; baseline, 298 ± 58 ms vs
CCh i ≠ 0, 775 ± 83 ms, p < 0.001). With current injection
removed and membrane potential allowed to depolarise, spike
probability increased slightly but failed to return to baseline levels
(Supplementary Fig. S6A1–C1; Pspike 0.33 ± 0.05, p < 0.05 baseline
vs CCh i= 0). In contrast, CCh application had little effect on TA
pathway driven spike probability and delay to the first spike when
the membrane potential was maintained at baseline levels
(Supplementary Fig. S6A2–C2; Pspike baseline, 0.33 ± 0.06 vs
CCh i ≠ 0, 0.43 ± 0.08, n= 15 from 10 mice, p > 0.05; delay to
spike baseline, 397 ± 56 ms vs CCh i ≠ 0, 483 ± 66 ms, p > 0.05).
However, with current injection removed and CA1 neurons
allowed to depolarise spike probability increased and the delay to
the first spike shortened (Supplementary Fig. S6A2–C2; Pspike
0.61 ± 0.06, p < 0.01 vs baseline; delay to spike 280 ms ± 27 ms,
p < 0.05 vs baseline).
Since endogenous acetylcholine reduces excitatory synaptic
inputs from the SC and TA pathways equally (Figs. 1 and 2), our
data suggest the acetylcholine-induced increase in spike prob-
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dependent depression of feedforward inhibition, and therefore
increase in excitatory–inhibitory balance, selectively in the TA
pathway (Fig. 2). Indeed, a substantial hyperpolarising envelope
driven by inhibitory synaptic inputs was seen in spike probability
recordings from both SC and TA pathways and could be removed
by application of a GABAA receptor antagonist (picrotoxin,
50 µM) (Fig. 7A, B; SC hyperpolarising envelope −2.45 ± 0.63
mVs, n= 15 from 5 mice vs SC GABAA antagonist −0.10 ± 0.66
mVs, n= 7 from 2 mice, p < 0.05; TA hyperpolarising envelope
−3.01 ± 0.46 mVs, n= 23 from 9 mice vs TA GABAA antagonist
−1.19 ± 0.52 mVs, n= 7 from 2 mice, p < 0.05). To test the
importance of inhibition for prioritisation of TA inputs by
acetylcholine we next repeated spike probability experiments in
the presence of the GABAA receptor antagonist. Under these
experimental conditions, SC pathway behaved similarly to the
absence of GABAA receptor antagonist, decreasing spike genera-
tion probability upon light stimulation of cholinergic fibres
(Fig. 7C–E; normalised SC decrease 0.76 ± 0.04 n= 13 from 7
mice, p < 0.01). In contrast, the TA pathway, which increased
Pspike after light stimulation when PSP included both excitatory
Fig. 5 Presynaptically located cholinergic receptors mediate TA EPSC reduction at CA1 pyramidal neurons. A Schematic illustrating GDP-β-S blockade of
GPCR function by inclusion in the recording pipette. B, C GDP-β-S blocks Carbachol (CCh, 10 µM)-induced depolarisation of membrane potential (Vm, left) and
reduction of input resistance (Rin, right) (control, n= 21 from 13 mice, GDP-β-S, n= 7 from 3 mice, two-tailed unpaired t-tests, Vm p=0.025, Rin p=0.009).
D Schematic illustrating pharmacological isolation of EPSCs from TA pathway and example traces showing depression by CCh (10 µM) in the presence of GDP-
β-S. E Schematic illustrating the putative role of GABA spillover from neighbouring synapses on presynaptic TA pathway terminals and example traces showing
depression of EPSCs by CCh in the presence of GABA receptor antagonists picrotoxin (PTX, 50 µM) and CGP55845 (5 µM). F Schematic illustrating putative
action of retrograde endocannabinoids on presynaptic TA pathway terminals and example traces showing depression of EPSCs by CCh in the presence of CB1
receptor antagonist AM251 (1 µM) and GABA receptor antagonist picrotoxin (50 µM). G, H Quantification of EPSC depression by CCh (G CCh, n= 21 from 13
mice, p < 0.0001; CCh+GDP-β-S, n= 7 from 3 mice, p < 0.0001; CCh+ PTX+CGP, n= 9 from 4 mice, p < 0.0001; CCh+ PTX+AM251, n= 12 from 4 mice,
p < 0.0001; CCh vs CCh+GDP-β-S, p=0.31; CCh vs CCh+ PTX+GDP, p=0.26; CCh vs CCh+ PTX+AM251, p=0.002) and change in PPR (H CCh,
n= 21 from 13 mice, p=0.006; CCh+GDP-β-S, n= 7 from 3 mice, p=0.047; CCh+ PTX+CGP, n= 9 from 4 mice, p=0.007; CCh+ PTX+AM251, n= 12
from 4 mice, p=0.017; CCh vs CCh+GDP-β-S, p=0.18; CCh vs CCh+ PTX+GDP, p=0.31; CCh vs CCh+ PTX+AM251, p=0.79; inter-group
comparisons one-way ANOVA with post hoc Bonferroni correction. Within-group comparisons two-tailed paired t-test). Data are mean ± SEM; **p < 0.01,
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Fig. 6 Endogenous acetylcholine release enhances CA1 response to temporoammonic over Schaffer collateral input. A Responses in CA1 pyramidal
neurons to 10 stimuli at 10 Hz given to Schaffer collateral (SC, left columns) or temporoammonic (TA, middle columns) input pathways. Raster plots show
representative experiments where SC and TA pathways are stimulated alternately with trains of 10 stimuli. Light stimulation of cholinergic fibres (LED, 2 Hz
for 5 min) modulates SC and TA pathways spike generation. Cholinergic receptor antagonists, atropine (25 µM) and mecamylamine (50 µM) prevented
modulation of spike generation in SC and TA pathways by endogenous acetylcholine release (right columns). B Time course of spike probability modulation
on SC (green) and TA (purple) pathway by the endogenous release of acetylcholine. C, D Quantification of spike probability (C) and time to first spike (D)
modulation on SC and TA pathways in the absence or presence of cholinergic antagonists (SC spike probability, n= 13 from 8 mice, p= 0.017; TA spike
probability, n= 14 from 7 mice, p= 0.0002; SC vs TA spike probability, p= 0.046; cholinergic antagonists, SC spike probability, p= 0.70; TA spike
probability, p= 0.40; SC time to first spike, n= 13 from 8 mice, p= 0.010; TA time to first spike, n= 14 from 7 mice, p= 0.0004; SC vs TA time to first
spike, p= 0.031; cholinergic antagonists, SC spike probability, p= 0.07; TA spike probability, p= 0.12). Data are mean ± SEM; inter-group comparisons
one-way ANOVA with post hoc Tukey’s correction. Within-group comparisons two-tailed paired t-test ***p < 0.001 *p < 0.05. Source data are provided as
a Source Data file.
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and inhibitory drive, yielded a similar spike probability outcome
to baseline when inhibition was blocked, slightly decreasing spike
probability (Fig. 7C–E; normalised TA decrease 0.88 ± 0.23,
n= 12 from 6 mice, p > 0.05).
Similar results were obtained using an exogenous application of
10 µM CCh with inhibition blocked. For the SC pathway, CCh
decreased spike generation probability when membrane potential
was kept unaltered (Supplementary Fig. S5D1; baseline, 0.7 ± 0.06
and CCh i ≠ 0, 0.21 ± 0.06, n= 9 from 3 mice, p < 0.01) and
showed an increase during depolarisation without reaching
baseline levels (0.44 ± 0.07, p < 0.05 vs baseline), which was
correlated with delay to first spike (baseline, 318 ms ± 67 ms, CCh
i ≠ 0, 673 ms ± 122ms, CCh i= 0, 397 ms ± 92 ms, p < 0.05
baseline vs CCh i ≠ 0). In contrast, the TA pathway, which
increased Pspike after CCh when PSP included both excitatory and
inhibitory drive, yielded a similar spike probability outcome to SC
pathway when inhibition was blocked, decreasing spike prob-
ability whether membrane potential was depolarised or not
(Supplementary Fig. S6D2; baseline, 0.58 ± 0.06; CCh i ≠ 0,
0.17 ± 0.05; CCh i= 0, 0.37 ± 0.08; n= 8 from 4 mice; p < 0.01
baseline vs CCh i ≠ 0 and p < 0.05 baseline vs CCh i= 0). This
was associated with increases in the delay to first spike
(Supplementary Fig. S6C2, D2; baseline 246 ms ± 23 ms; CCh
i ≠ 0, 631 ms ± 119 ms; CCh i= 0, 464 ms ± 119ms; p < 0.05
baseline vs CCh i ≠ 0).
Altogether, our data indicate that cholinergic receptor activa-
tion produces a decrease of spike output in response to SC activity
while enhancing output in response to TA activity via a
differential effect on feedforward inhibition to CA1.
Discussion
A long-standing and influential theory proposes that acetylcho-
line release in the hippocampus prioritises novel sensory infor-
mation input to enable incorporation into memory ensembles10.
This theory is based on computational modelling and the
observation that SC synaptic inputs are more sensitive than TA
inputs to depression caused by exogenous cholinergic
agonists10,11,20,21. In contrast, we show that excitatory synaptic
transmission at SC and TA inputs to CA1 are equally depressed
by endogenous acetylcholine released in response to optogenetic
stimulation (Fig. 1). Furthermore, in the absence of inhibition, we
show that this results in a dramatic reduction of spike output
from CA1 in response to either SC or TA input (Fig. 7). However,
when we considered the effects of acetylcholine on local inhibi-
tory networks as well as excitatory inputs, we find that acet-
ylcholine depresses feedforward inhibition in the TA pathway
more than the SC pathway over the course of a burst of stimuli
(Figs. 2 and 3). This results in an overall enhancement of spike
output from CA1 in response to TA input but not the SC input
(Fig. 6) supporting the hypothesis that acetylcholine enhances
responses to novel sensory information arriving via the TA
pathway.
The regulation of local inhibitory networks by acetylcholine is
therefore central to prioritisation of TA inputs by acetylcholine
and differences in the regulation of synaptic output from inter-
neuron subtypes are a critical factor. Although the interneuron
subtypes engaged by the SC and TA pathways are a mixed
population highlighted by their dendritic arbours extending into
both stratum radiatum and stratum lacunosum moleculare
(Supplementary Fig. S8), the difference in IPSC kinetics and
sensitivity to the µ-opioid receptor agonist DAMGO in our
recordings support previous findings that PV+ cells form the
majority of feedforward inhibition in the SC pathway whereas
CCK+ cells are the major contributors to feedforward inhibition
in the TA pathway34–38. There is potential for slice orientation to
affect interneuron connectivity networks, but these findings
appear to be independent of slicing angle. Care must also be taken
















































































Fig. 7 Cholinergic enhancement of CA1 responses to temporoammonic inputs is mediated by inhibition. A, B Inhibition of GABAA receptors with
picrotoxin (50 µM) reduced the underlying hyperpolarising envelope (red) in response to 10 stimuli at 10 Hz for both SC (green; control, n= 15 from 5
mice; GABAA antagonist, n= 7 from 2 mice; p= 0.028, two-tailed unpaired t-test) and TA (purple; control, n= 23 from 9 mice; GABAA antagonist, n= 7
from 2 mice; p= 0.021, two-tailed unpaired t-test) input pathways to CA1 pyramidal neurons. C–E In the presence of a GABAA receptor antagonist, light
stimulation of cholinergic fibres (LED) reduced spike probability for SC pathway but produced no change in the TA pathway (SC spike probability, n= 13
from 7 mice, p= 0.005; TA spike probability, n= 12 from 6 mice, p= 0.38; SC vs TA spike probability, p= 0.37; inter-group comparisons one-way
ANOVA with post hoc Bonferroni correction. Within-group comparisons two-tailed paired t-test). Data are mean ± SEM; **p < 0.01, *p < 0.05. Source data
are provided as a Source Data file.
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interneuron populations54, but our evidence and that of other
groups suggests the overlap is small38,55–57. Crucially, the
synaptic output from PV+ and CCK+ interneurons is differen-
tially regulated by acetylcholine. Whilst both outputs are
depressed by acetylcholine, the depression of CCK+ output is
greater over the course of a burst of stimuli showing enhanced
depression for later responses in the burst, mirroring the effect of
acetylcholine on feedforward inhibition in the TA pathway.
Acetylcholine does not cause a greater depression for later
responses in the burst for PV+ synaptic output and therefore
feedforward inhibition in the SC pathway is relatively greater over
a burst of stimuli reducing the impact of SC stimulation when
acetylcholine is present. Interestingly, the excitability of different
interneuron subtypes is regulated by different cholinergic recep-
tors with M3 receptors in CCK+ interneurons, M1 receptors in
PV+ and NPY+ interneurons and nicotinic α2 receptors in OLM
feedback interneurons30–32,39,58. This further supports the major
contribution of CCK+ interneurons in the TA pathway since the
M3 receptor antagonist DAU5884 completely blocked the CCh-
induced depression of feedforward inhibition in the TA pathway.
An alternative mechanism for cholinergic regulation of CA1
pyramidal cell output is direct modulation of dendritic excit-
ability. Cholinergic receptors modulate multiple ion channels
including HCN, Kv4.2, Kv7, SK and R-type Ca2+ channels that
broadly enhance dendritic excitability, for example by increasing
HCN or Ca2+ channel function or inhibiting K+ channels12,59–62.
These actions might be expected to increase spike output in
response to synaptic input and it is possible that specific dis-
tributions of channels along the proximal-distal dendritic axis
could result in enhancement of TA vs SC inputs. However, we
note that in our voltage-clamp experiments the internal solution
blocked most of these conductances and that blockade of inhi-
bitory synaptic transmission prevented the change in SC and TA
input influence leaving little role for direct enhancement of
dendritic excitability. These mechanisms may play a greater role
in the facilitation of long-term synaptic plasticity12,63.
The differential regulation of SC and TA pathways is mediated
by selective expression of M4 and M3 receptors. The targeting of
M3 and M4 receptors to presynaptic terminals of TA and SC
axons, respectively, fits with a broader picture of highly specific
localisation of muscarinic receptor subtypes to cellular and sub-
cellular domains within the hippocampus that includes the
localisation of M2 receptors to inhibitory presynaptic terminals of
PV+ basket cells. This agrees with the observed highly laminar
localisation of M3 receptors in the Stratum Lacunosum Molecu-
lare, M4 receptors in Stratum Radiatum and M2 receptors in the
Stratum Pyramidale51 (but see ref. 28). At each terminal, mus-
carinic receptors depress neurotransmitter release
probability27,29,33,51 and we show that this includes M3 receptors
in the TA pathway. We tested whether these M3 receptors directly
modulate presynaptic terminals of TA axons to depress the
release of glutamate or indirectly modulate by causing the release
of a retrograde messenger (Fig. 5). M3 receptors are also
expressed in CCK+ interneurons where they increase
excitability31,32 and our data suggest that M3 receptors expressed
in these cells can also regulate the release of GABA at synapses
onto pyramidal cells (Figs. 3 and 4). However, an increase in
GABA release and spillover onto presynaptic GABAB receptors
does not explain the modulation of presynaptic function (Fig. 5).
Another potential mechanism for presynaptic regulation by
acetylcholine is via endocannabinoid release and presynaptic CB1
receptors64. This is best characterised at inhibitory CCK synapses
onto pyramidal cells where endocannabinoid release depresses
transmission and increases PPR65. In our experiments, PPR
does not increase (Fig. 3) and excitatory TA pathway transmis-
sion was still depressed by CCh in the presence of the CB1
receptor antagonist with only a minor reduction in the amount of
depression (Fig. 5). Therefore, our data do not support a major
role for endocannabinoids in cholinergic modulation of synaptic
transmission. By ruling out these indirect mechanisms we con-
clude that M3 receptors most likely act directly at presynaptic
terminals of TA axons to depress the release of glutamate.
Given the importance of the TA input for synaptic plasticity in
the hippocampus26,66 it is expected that M3 receptors play an
important role in hippocampal-dependent learning. However, the
evidence from studies using mice with genetic deletion of M3
receptors is somewhat equivocal53,67. A potential explanation lies
in the compensation for deletion of M3 with the expression of M1
receptors (Supplementary Fig. S4) that couple to similar Gq-
mediated signalling pathways and it is interesting that knockin
mutations of phosphorylation-deficient M3 receptors with
potentially less compensation show greater effects on learning
and memory67. The compensation for M3 deletion by M1
receptors is somewhat surprising since M1 receptors are generally
expressed widely in somatic and dendritic cellular domains in
pyramidal cells and interneurons where they regulate intrinsic
excitability leading to effects on synaptic plasticity and network
oscillations12,14–16,51,68–71 but are not generally found in pre-
synaptic terminals72.
Cholinergic neurons in vivo fire at frequencies ranging from
0.3 to 5 Hz with higher frequencies recorded during waking
activity73,74. Responses to salient events such as positive or
negative reinforcement have been demonstrated7,74,75 and there is
evidence to suggest that acetylcholine release can be functionally
targeted to specific regional or cellular domains at behaviourally
relevant timepoints42,74,76,77. Equally, other evidence indicates
substantial synchronicity of acetylcholine release between and
within brain regions7,19,74,75,78. Even at behaviourally relevant
timepoints, cholinergic firing rates do not increase markedly but
rather activity across cholinergic neurons is synchronised or
occurs in short bursts74,77. Interestingly, the release of acet-
ylcholine plateaus at firing rates around 2 Hz44 indicating that the
dynamic range of acetylcholine release occurs at frequencies
below 2 Hz. Therefore, optogenetic stimulation that synchronises
release at 2 Hz over extended time periods is likely to be phy-
siologically maximal and relevant to the functional reorganisation
of hippocampal networks regardless of the specificity of choli-
nergic targeting. Cholinergic neurons are also reported to co-
release glutamate and more prominently GABA both from long-
range projections and also local cholinergic interneurons41,42,79.
However, we found no evidence for glutamate or GABA release
after optogenetic stimulation of cholinergic fibres (Fig. 1D).
Therefore, under our experimental conditions, optogenetic sti-
mulation of cholinergic fibres at 2 Hz likely provides a maximally
effective release of acetylcholine without co-release of glutamate
or GABA that can be mimicked by exogenous application of
10 µM CCh.
Acetylcholine increases the output gain from primary sensory
cortices enhancing signal-to-noise for new sensory information
and desynchronising the local cortical network by reorganising
inhibition to disinhibit pyramidal neurons17–19. A contrary
situation is reported in the hippocampus where cholinergic
activation of dendritically targeting interneurons inhibits pyr-
amidal neurons and potentially gates CA1 output30,75,80. Both of
these mechanisms may be important for learning new repre-
sentations, however, neither of these situations addresses whether
acetylcholine prioritises one set of inputs over another. This is
important if one considers the role of CA1 as a comparator
between learned representations in CA3 and a structural frame-
work for sensory inputs from the entorhinal cortex81. Here, we
reveal a mechanism whereby acetylcholine alters the short-term
dynamics of information processing in CA1 by acting on two
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distinct muscarinic receptor subtypes located in the SC and TA
pathways. This potentially reduces the role of learned repre-
sentations encoded in the CA3 network in driving the output of
CA1 and it will be interesting to discern in future how these
various mechanisms interact across different behavioural epochs.
Multiple compounds have been developed to selectively target
M1 and M4 muscarinic receptors for potential cognitive
enhancement whereas M2 and M3 receptors have received much
less attention due to complications with peripheral effects on
cardiac and enteric function. The M1/M4 receptor dual agonist
Xanomeline has cognitive-enhancing and antipsychotic efficacy
in clinical trials82,83 and whilst it is not clear whether M1 or M4
receptors are the key target, in separate studies, selective M1
agonists and M4 agonists have been shown to have memory-
enhancing and/or antipsychotic efficacy84,85 whereas deletion of
M1 receptors in mice causes memory deficits86. Our data provide
a mechanism for the actions of M1/M4 receptor dual agonists
such as Xanomeline and Compound 1 where activation of M1
receptors facilitates synaptic plasticity12 and activation of M4
receptors prioritises new information to incorporate into mem-
ory. Our data also predict that selective activation of M3 receptors
could potentially facilitate the consolidation of memory by
reducing interference from new information. Interestingly, the
link that we demonstrate between selective muscarinic receptor
activation and distinct interneuron subtypes suggests a mechan-
ism to selectively target and regulate these interneuron popula-
tions. This could have therapeutic value in disorders with
disruption to specific interneuron populations such as PV+
neurons in schizophrenia87. Overall, acetylcholine release in the
hippocampus supports cognition and the identification of specific
roles for each muscarinic receptor subtype provides mechanisms
to selectively modulate individual aspects of acetylcholine’s
actions. The identification of M3 receptors as regulators of TA
inputs in contrast to M4 receptors acting on SC inputs provides a
mechanism by which specific targeting of these muscarinic
receptors could represent a therapeutic strategy to bias hippo-
campal processing and enhance cognitive flexibility.
Methods
Animal strains. All experiments were performed using male mice. C57BL/6J
(Charles River) mice were used as the background strain. The generation of the M3
receptor KO mice (CHRM3 KO) has been described53. The M3 KO mice used for
this study had been backcrossed for ten times onto the C57BL/6NTac background.
Cre reporter allele mice (The Jackson Laboratory) were used to tag specific neu-
ronal populations: Cholinergic neurons (Chat-IRES-Cre; Stock No. 006410), par-
valbumin interneurons (B6 PVCRE; Stock No. 017320) and cholecystokinin
interneurons (CCK-IRES-Cre; Stock No. 012706). Homozygous cre reporter mice
were crossed with homozygous Ai32 mice (B6.Cg-Gt(ROSA)26Sortm32(CAG-
COP4*H134R/EYFP)Hze/J; Stock No. 024109) to generate litters of heterozygous
offspring expressing ChR2.
Slice preparations. All animal procedures were performed in accordance with
Home Office guidelines as stated in the United Kingdom Animals (Scientific Pro-
cedures) Act 1986 and EU Directive 2010/63/EU 2010 and experimental protocols
were approved by the British National Committee for Ethics in Animal Research.
Brain slices were prepared from P30-40 male mice. Following cervical
dislocation and decapitation, brains were removed and sliced in ice-cold sucrose
solution containing (in mM): 252 sucrose, 10 glucose, 26.2 NaHCO3, 1.25
NaH2PO4, 2.5 KCl, 5 MgCl2 and 1 CaCl2 saturated with 95% O2 and 5% CO2.
Parasagittal slices 350 µm thick were cut using a VT1200 (Leica) vibratome. Slices
were transferred to warm (32 °C) aCSF for 30 min containing (in mM): 119 NaCl,
10 glucose, 26.2 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 1.3 MgSO4 and 2.5 CaCl2
saturated with 95% O2 and 5% CO2 and then kept at room temperature until use.
Electrophysiology. Whole-cell patch-clamp recordings were made from hippo-
campal CA1 pyramidal neurons visualised under infra-red differential interference
contrast on SliceScope Pro 6000 system (Scientifica). CA1 pyramidal neuron
identity was verified by measurement of capacitance, input resistance and mem-
brane potential. Neurons in the medial septum were patched blind to genotype.
Slices were continually perfused with aCSF at 4–5 ml/min. Patch electrodes (4–7
MΩ resistance) were pulled from borosilicate glass capillaries (Harvard Apparatus)
using a PC-87 Micropipette puller (Sutter Instrument). Recording pipettes were
filled with either voltage-clamp internal solution (in mM: 117 CsMeSO3, 9 NaCl, 10
HEPES, 10 TEA, 2 MgATP, 0.3 NaGTP, 1 QX-314, 0.3 EGTA at pH 7.3 and
290 mOsm) or current-clamp internal solution (in mM: 135 K-Gluconate, 10
HEPES, 7 glucose, 8 NaCl, 2 MgATP, 0.3 NaGTP, 0.2 EGTA at pH 7.3 and
290 mOsm). In some experiments, GDP-β-S was included in the internal solution
and allowed to diffuse for at least 15 min before application of carbachol to ensure
equal concentration in all cellular compartments. Electrophysiological recordings
were made with an Axoclamp 200B (Molecular Devices) filtered at 5 kHz and
digitised at 10 kHz using a CED micro 1401 MKII board and Signal5 acquisition
software (Cambridge Electronic Design). Series and input resistances were mon-
itored by applying a 20 pA and 500 ms square pulse. Experiments where neurons
displayed >25% change in series resistance were discarded from subsequent ana-
lysis. Membrane potentials were not corrected for junction potentials.
Dual pathway (SC and TA) stimulation. Bipolar stimulating electrodes were
placed in CA3 to stimulate SC fibres and in the Stratum Lacunosum Moleculare
(SLM) of subiculum to stimulate TA fibres. Synaptic responses were evoked
alternately in either pathway at 15 s intervals. Monosynaptic EPSCs were recorded
either at −65 mV membrane potential in the presence of GABAA receptor blocker
picrotoxin (50 µM) or in control aCSF at the experimentally determined reversal
potential for GABAA receptors (−60 mV). Disynaptic IPSCs were recorded in
control aCSF at experimentally determining reversal potential for AMPA receptors
(0 mV). NBQX (20 µM) was applied at the end of experiments to ascertain the
contribution of direct stimulation of local interneurons to IPSCs and only
responses which showed >70% reduction in IPSCs were used for analysis. In the
experiments specified, SC and TA pathway EPSCs and IPSCs were recorded from
the same CA1 pyramidal neuron to calculate the excitation–inhibition ratio (E–I
ratio). EPSC and IPSC contributions were measured as charge transferred by
calculating the area of each synaptic response in pC and the ratio of EPSC and
IPSC charge for each response determined the E–I ratio. PPRs were calculated by
normalising the amplitude of each response to the first response. TA over SC E–I
ratio was calculated for each cell before averaging across cells.
Current-clamp experiments were performed at resting membrane voltage
(−61.3 ± 3.5 mV). TA and SC pathways were stimulated at intervals of 20 s with
trains of 10 stimuli at 10 Hz. Stimulation intensities were set to generate target
spike probabilities between 30 and 70%. Spike probability was calculated as the
number of spikes/number of stimuli. Time to first spike was measured from the
first stimulus in the train. The post-synaptic potential (PSP) envelope was
measured by calculating the area under the curve generated by joining the points of
maximum hyperpolarisation in response to each stimulation as described
previously88. Carbachol (CCh 10 µM)-induced depolarisations were neutralised by
current injections to maintain a constant membrane voltage (i ≠ 0). To investigate
the impact of CCh-induced depolarisation, the injected current was removed
(i= 0).
Optogenetic stimulation. Blue light from a 470 nm LED was targeted to slices via
a 469 nm emission filter, a GFP dichroic mirror (Thorlabs) and the 4× (ChAT-
Ai32) or 40× (PV-Ai32 or CCK-Ai32) microscope objective. 5 ms light pulses at
7–9 mW/mm2 intensity were used for all stimuli. Optogenetically evoked IPSCs
were recorded from pyramidal neurons at 0 mV membrane potential in the pre-
sence of the AMPA and NMDA receptor antagonists NBQX (10 µM) and DAPV
(50 µM).
Confocal imaging. Recorded slices were permeabilized with 0.1% Triton X-100
(Sigma) and incubated with Alexa avidin (488 or 594 nm; ThermoFisher). CA1
pyramidal neurons from Chat-Ai32 mice were labelled with Alexa-594 and test
proximity to cholinergic axons using Chat-Ai32 YFP fluorescence.
Statistical analysis. The experimental unit was defined as a cell for all conditions
and only one cell was recorded from each slice. Cell and animal numbers are
reported for all experiments. All data were plotted as the mean ± SEM. Where
comparisons between two conditions were made paired or unpaired two-tailed
Student’s t-tests were applied as appropriate. For comparisons between more than
two conditions one-way repeated measures ANOVA tests with Bonferroni post hoc
correction were used. The level of significance was set to 0.05 and p-values are
shown as follows: *p < 0.05; **p < 0.01; ***p < 0.001. Experiments on CHRM3 WT
and CHRM3 KO mice were performed blind to genotype.
Reagents. Carbachol (CCh), CGP55845, NBQX, DCG-IV, D-APV, picrotoxin,
atropine, mecamylamine, nitrocaramiphen, DAU5884, AM251, GDP-β-S were
purchased from Tocris (UK). GSK-5 was synthesised in-house at Eli Lilly and Co.
Stock solutions of these compounds were made by dissolving in water. The
selective muscarinic M1 and M4 receptor agonist Compound 1 was synthesised in-
house at Sosei Heptares and dissolved in DMSO for stock solution. The purity of
the final compounds was determined by HPLC or LC/MS analysis to be >95%.
Additional experimental details relating to the synthesis of Compound 1 and
associated structures are described in detail in WO2015/118342 which relates to the
invention of agonists of the muscarinic M1 receptor and/or M4 receptor and which
are useful in the treatment of muscarinic M1/M4 receptor-mediated diseases.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Further information and data that support the findings of this study are available upon
reasonable request from the corresponding author Jack.Mellor@bristol.ac.uk. Source data
are provided with this paper.
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